RxDoctor Payments Data

Eleanor Orehek, MD

Neurology · Bloomington, MNNPI 1194980045

Payments from drug & device makers

$55,265in general payments, 2019–2025

Across 68 payments — averaging $812.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acorda Therapeutics, Inc$33K
  • Amneal Pharmaceuticals LLC$21K
  • Medtronic$1K
  • Boston Scientific$312
$1,605in research payments, 2019–2025

Across 2 payments — averaging $802.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$2K

What the payments were for

  • Consulting fees$3251%
  • Speaking & faculty fees$52,55895%
  • Travel & lodging$8782%
  • Food & beverage$1,5043%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Acorda Therapeutics, Inc27$32,735
Amneal Pharmaceuticals LLC19$21,086
Medtronic(2 entities)17$1,133
Boston Scientific5$312

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$55,265 in reported general payments places this provider in the 85th percentile of 434 neurology providers in Minnesota.

See all neurology providers in Minnesota

Medicare billing

Part B allowed, 2024
$691,039
Medicare patients
573
Services billed
28,841

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa240$368,608
IngrezzaValbenazine Tosylate47$346,915
NuplazidPimavanserin Tartrate45$200,172
InbrijaLevodopa53$154,036
Carbidopa-LevodopaCarbidopa/Levodopa1,785$101,333
Carbidopa-Levodopa ErCarbidopa/Levodopa702$46,485
NeuproRotigotine27$27,778
Tetrabenazine38$25,415
Diazepam77$24,451
Ajovy AutoinjectorFremanezumab-Vfrm17$12,258
Rasagiline Mesylate65$10,515
Primidone228$6,441
RivastigmineRivastigmine Tartrate53$5,693
Gabapentin193$5,374
Entacapone41$4,781

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$21,086$368,608240 claims
Acorda Therapeutics, IncInbrija$32,735$154,03653 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 434 neurology providers in Minnesota.

Other neurology in Bloomington

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →